Myeloma2018 Session VII

 

Genomics of Drug Resistance

In session VII of Myeloma2018, the underlying genomics and proteomics of drug resistance in MM are investigated. Arun Wiita, MD, PhD, Brian Van Ness, PhD, Marc Raab, MD, Mike Chapman, PhD, Florian Bassermann, MD, PhD, and Anja Seckinger, MD, discuss the resistance of various proteasome inhibitors and immunomodulatory drugs, with reference to bone marrow signaling mechanisms, plasma cell tumor sensitivities, and driver gene mutations.

Presentations
Proteomics of Drug Resistance in Multiple Myeloma
Arun Wiita, MD, PhD
University of California, San Francisco, CA
9 September, 2018

Arun Wiita, MD, PhD, from the University of California, San Francisco, CA, discusses the proteomics of drug resistance.

Genetics of Drug Resistance Proteasome Inhibitors
Brian Van Ness, PhD
University of Minnesota, Minneapolis, MN
9 September, 2018

Brian Van Ness, PhD, from the University of Minnesota, Minneapolis, MN, speaks about proteasome inhibitor resistance.

Genetic Analysis of Refractory Multiple Myeloma
Marc Raab, MD
University of Heidelberg, Heidelberg, Germany
9 September, 2018

Marc Raab, MD, from the University of Heidelberg, Heidelberg, Germany, speaks about the genetic analysis of refractory multiple myeloma.

A Seven-gene Classifier for Bortezomib or Lenalidomide Responsiveness
Michael Chapman, PhD
University of Cambridge, Cambridge, UK
9 September, 2018

Mike Chapman, PhD, from the University of Cambridge, Cambridge, UK, explores the signatures of drug resistance.

IMiDs: Mechanisms of Resistance and Metabolism
Florian Bassermann, MD, PhD
Technical University of Munich, Munich, Germany
9 September, 2018

Florian Bassermann, MD, PhD, from the Technical University of Munich, Munich, Germany, discusses IMiD resistance and metabolism.

CD38 Sensitivity and (Upfront) Resistance
Anja Seckinger, MD
University of Heidelberg, Heidelberg, Germany
9 September, 2018

Anja Seckinger, MD, from the University of Heidelberg, Heidelberg, Germany, presents interesting information for CD38 sensitivity and resistance.